CAS 76-43-7|Fluoxymesterone
| Common Name | Fluoxymesterone | ||
|---|---|---|---|
| CAS Number | 76-43-7 | Molecular Weight | 336.441 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 474.2±45.0 °C at 760 mmHg |
| Molecular Formula | C20H29FO3 | Melting Point | 240 °C |
| MSDS | / | Flash Point | 240.6±28.7 °C |
| Symbol | GHS02, GHS07, GHS08 | Signal Word | Danger |
Names
| Name | Fluoxymesterone |
|---|---|
| Synonym | More Synonyms |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 474.2±45.0 °C at 760 mmHg |
| Melting Point | 240 °C |
| Molecular Formula | C20H29FO3 |
| Molecular Weight | 336.441 |
| Flash Point | 240.6±28.7 °C |
| Exact Mass | 336.210083 |
| PSA | 57.53000 |
| LogP | 2.17 |
| Vapour Pressure | 0.0±2.7 mmHg at 25°C |
| Index of Refraction | 1.562 |
| InChIKey | YLRFCQOZQXIBAB-RBZZARIASA-N |
| SMILES | CC1(O)CCC2C3CCC4=CC(=O)CCC4(C)C3(F)C(O)CC21C |
| Water Solubility | NEGLIGIBLE |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 400 ug/kg
- TOXIC EFFECTS :
- Lungs, Thorax, or Respiration - other changes Skin and Appendages - dermatitis, other (after systemic exposure) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 2350 mg/kg
- TOXIC EFFECTS :
- Behavioral - altered sleep time (including change in righting reflex) Behavioral - changes in motor activity (specific assay)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 437500 ug/kg/35D-C
- TOXIC EFFECTS :
- Blood - changes in leukocyte (WBC) count Endocrine - adrenal cortex hypoplasia Endocrine - changes in thymus weight
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 12 mg/kg
- SEX/DURATION :
- male 84 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 800 mg/kg
- SEX/DURATION :
- female 3-10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - abortion
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 500 mg/kg
- SEX/DURATION :
- female 3-7 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 8 mg/kg
- SEX/DURATION :
- male 10 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 438 mg/kg
- SEX/DURATION :
- male 35 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - testes, epididymis, sperm duct
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 6 mg/kg
- SEX/DURATION :
- female 17-20 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - urogenital system
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 16 mg/kg
- SEX/DURATION :
- male 10 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Paternal Effects - other effects on male
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 12 mg/kg
- SEX/DURATION :
- female 3 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 20 mg/kg
- SEX/DURATION :
- female 10 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
- TYPE OF TEST :
- Micronucleus test
MUTATION DATA - TEST SYSTEM :
- Rodent - mouse
- DOSE/DURATION :
- 100 ug/kg
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 342,103,1995 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5630 No. of Facilities: 18 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 403 (estimated) No. of Female Employees: 179 (estimated)
- TEST SYSTEM :
- Rodent - mouse
- DOSE/DURATION :
- 100 ug/kg
- REFERENCE :
- MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 342,103,1995 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5630 No. of Facilities: 18 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 403 (estimated) No. of Female Employees: 179 (estimated)
Safety Information
| Symbol | GHS02, GHS07, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H315-H360FD |
| Supplemental HS | May form explosive peroxides. |
| Precautionary Statements | P201-P210-P280-P308 + P313-P370 + P378-P403 + P235 |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R63 |
| Safety Phrases | S22-S36-S24/25 |
| RIDADR | UN2252 - class 3 - PG 2 - 1,2-Dimethoxyethane solution |
| WGK Germany | 3 |
| RTECS | BV8390000 |
| HS Code | 2937290018 |
Customs
| HS Code | 2937290018 |
|---|
Articles25
More Articles| Rat liver lysosomal and mitochondrial activities are modified by anabolic-androgenic steroids. Med. Sci Sports Exerc. 31 , 243, (1999) The aim of this study was to examine the separate and combined effects of an 8-wk treatment with high doses of 17alpha-alkylated anabolic-androgenic steroids (AAS) and exercise training on selected ly... | |
| Biotransformation of 17-alkyl steroids in the equine: high-performance liquid chromatography-mass spectrometric and gas chromatography-mass spectrometric analysis of fluoxymesterone metabolites in urine samples. J. Chromatogr. B. Biomed. Sci. Appl. 704 , 119, (1997) In this study the equine metabolism of fluoxymesterone (9alpha-fluoro-11beta-17beta-dihydroxy-17alpha-meth ylandrost-4-ene-3-one) given orally has been investigated. The parent material was not detect... | |
| Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J. Clin. Oncol. 18(2) , 262-6, (2000) Although hormonal therapy represents standard therapy for metastatic hormone-sensitive disease, many patients receive initial chemotherapy because of the location, bulk, or aggressiveness of their dis... |
Synonyms
| 11b,17b-Dihydroxy-9a-fluoro-17a-methyl-4-androsten-3-one |
| (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one |
| Testosterone, 9-fluoro-11β-hydroxy-17-methyl- |
| 9a-Fluoro-11b-hydroxy-17a-methyltestosterone |
| MFCD00010480 |
| 9α-Fluoro-11β-hydroxy-17-methyltestosterone |
| (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one |
| Androst-4-en-3-one, 9-fluoro-11β,17β-dihydroxy-17-methyl- |
| Halotestin |
| EINECS 200-961-8 |
| Androst-4-en-3-one, 9-fluoro-11,17-dihydroxy-17-methyl-, (11β,17β)- |
| fluoxymesterone |
| (8S,9R,10S,11S,13S,14S,17S)-9-Fluor-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-on |
| (11β,17β)-9-Fluoro-11,17-dihydroxy-17-methylandrost-4-en-3-one |
| (8S,9R,10S,11S,13S,14S,17S)-9-fluoro-11,17-dihydroxy-10,13,17-triméthyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tétradécahydro-3H-cyclopenta[a]phénanthrén-3-one |
